News search

The study describes an innovative probe for the noninvasive detection of macrophages using PET technology

iFlpMosaics is a new technology presented in Nature Methods that allows the modification and study of gene function in mouse models, advancing research on diseases caused by somatic mutations, such as cancer and vascular malformations.

RESILIENCE is a clinical trial funded by the European Commission (H2020 Programme) that aims to reduce the prevalence of heart failure in cancer survivors

The study, published in the journal JACC: CardioOncology, identifies mitochondrial function and heart metabolism as targets for possible treatments to protect against anthracycline-induced cardiotoxicity

Dr. Carla Rothlin is Dorys McConnell Duberg Professor of Immunobiology and Professor of Pharmacology at the Yale School of Medicine, and co-leader of the Cancer Immunology Programme at Yale Cancer Centre. She studied biochemistry and pharmacology at the University of Buenos Aires, where she also undertook her postgraduate research under the direction of Dr. Ana Belén Elgoyhen, focussing on nicotinic receptors expressed in the inner ear. Later, she completed her doctorate and moved to San Diego to join Dr. Greg Lemke’s laboratory at the Salk Institute for Biological Studies. In 2009, Dr. Rothlin was named Assistant Professor in Immunobiology at Yale Medical School

The new study, published in Nature Cardiovascular Research, will help to select the most effective and safe way to modulate angiogenesis in ischemic tissues or in cancer

A study published in Hepatology demonstrates that the activation of thermogenesis in the livers of obese mice contributes to weight loss and improves diabetes symptoms

 Over one million European cancer patients suffer from side effects to chemotherapy